Etherna

Recent Finacing

Series B II

Recent Raise

$38.9M

eTheRNA develops TriMix three‑mRNA immune‑stimulatory constructs, proprietary LNP/cLNP intravenous delivery formulations, mRNA T‑cell adjuvants, plus cGMP manufacturing and licensing services for oncology and infectious disease.

Founded 2018

Ticino, Switzerland

1-10

Private

etherna.io

Highlights

Focus Areas

Content Creators

Information Technology

Internet

Video

Web3

Recent Investors

G

Financials

$77.3M

Total Raised

2

Funding rounds

10

Investors

Team

Upgrade to view the team

See the team members at Etherna.